Jump to content

Array BioPharma

From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Array BioPharma
Company typeSubsidiary
Nasdaq: ARRY
IndustryOncology
Medication
Founded1998; 27 years ago (1998)
Founder
  • Drs. Tony Piscopio
  • Kevin Koch
  • David Snitman
  • K.C. Nicolaou
Headquarters,
United States
Revenue$173.8 million (2018)
ParentPfizer
Websitewww.arraybiopharma.com

Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.

History

In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.[1]

In November 2000, the company became a public company via an initial public offering.[2]

In June 2019, Pfizer acquired the company for approximately $11 billion.[3]

Discovery of FDA Approved Small Molecules

References

  1. ^ "Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company". BioSpace. Retrieved 2020-07-28.
  2. ^ "Array IPO up 17%". CNN. November 17, 2000.
  3. ^ "Pfizer acquires Array BioPharma, valued at $11.4 billion". Rappler. 18 June 2019. Retrieved 2020-07-29.